Potential role of microbiome in Chronic Fatigue Syndrome/Myalgic Encephalomyelits (CFS/ME).
Lupo, Giuseppe Francesco Damiano, Rocchetti, Gabriele, Lucini, Luigi et al. · Scientific reports · 2021 · DOI
Quick Summary
This study looked at the bacteria living in the gut and mouth of people with ME/CFS compared to healthy people. Researchers found that people with ME/CFS have different types and amounts of bacteria in their intestines, including fewer beneficial bacteria and more of certain harmful ones. They also found differences in the chemical makeup of patients' stool samples. These differences suggest that gut bacteria imbalance may play a role in ME/CFS, though scientists don't yet know if this is a cause or a result of the illness.
Why It Matters
ME/CFS patients lack clear biomarkers and effective treatments; identifying dysbiosis patterns offers potential diagnostic insight and suggests the microbiome as a therapeutic target. Understanding whether microbiota changes contribute to the energy metabolism dysfunction and immune abnormalities characteristic of ME/CFS could open new avenues for probiotic or dietary interventions.
Observed Findings
Reduced abundance of Lachnospiraceae family bacteria, particularly the genus Anaerostipes, in ME/CFS patients' fecal samples compared to controls
Increased abundance of Bacteroides and Phascolarctobacterium genera in ME/CFS fecal microbiota
Elevated Rothia dentocariosa in the oral microbiota of ME/CFS patients
High levels of glutamic acid and argininosuccinic acid in ME/CFS fecal metabolomic profiles
Decreased alpha-tocopherol (vitamin E) levels in ME/CFS patient stool samples
Inferred Conclusions
ME/CFS is associated with characteristic dysbiotic signatures in the intestinal microbiota that distinguish patients from healthy controls
Microbiota dysbiosis in ME/CFS affects multiple body sites, including both gut and oral cavities
Altered microbial composition correlates with abnormal metabolite profiles that may relate to energy metabolism dysfunction
Remaining Questions
Do the observed microbiota and metabolite changes cause ME/CFS symptoms, or do they result from the disease process?
Which specific microbial or metabolite changes, if any, directly contribute to immune dysfunction or energy metabolism abnormalities in ME/CFS?
What This Study Does Not Prove
This study demonstrates correlation between dysbiosis and ME/CFS but does not prove causation—the microbiota changes could be a consequence rather than a cause of the disease. The cross-sectional design cannot establish temporal relationships, and the authors cannot confirm whether these microbial signatures are specific to ME/CFS or related to its secondary symptoms versus primary pathology.
Tags
Symptom:Fatigue
Biomarker:MetabolomicsBlood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
Can these dysbiotic signatures be used clinically as biomarkers for ME/CFS diagnosis or disease severity?
Would microbiota-targeted interventions (probiotics, dietary modifications, fecal microbiota transplantation) improve ME/CFS symptoms in patients with these specific dysbiotic patterns?